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Summary The relationship of reproductive factors, such as nulliparous vs ever-parous status, age at first
birth, and total parity, with morphologic prevalence of fibrocystic changes were examined using autopsy
material from three ethnic/racial groups at varying risks for breast cancer. Although there was a trend toward
a protective effect of ever-parous status, there was no statistically significant difference in the prevalence of
fibrocystic disease in any group defined by parity status. The ethnic differences in the prevalence of fibrocystic
changes were not explained by the differences in parity status distribution for the three ethnic/racial groups.
Morphological fibrocystic changes have been associated with
an increased risk of development of breast cancer (Jensen et
al., 1976; Bartow et al., 1982; Love et al., 1982; Dupont &
Page, 1985; Hutter et al., 1986). Ever-parous vs nulliparous
status, early age at first full-term pregnancy and high total
parity are among factors that epidemiological studies have
identified as exerting protective effects on breast cancer risk
(MacMahon et al., 1970; Kelsey, 1979; Bain et al., 1981;
Lubin et al., 1982; Helmrich et al., 1983). The relationship
between these reproductive factors and fibrocystic disease is
unclear.
This study was undertaken to examine the relationship
between parity factors and prevalence of morphologic
fibrocystic changes. The case series was a subset from a
larger autopsy series in which the prevalence of morphologic
subsets of fibrocystic change was examined in three ethnic/
racial groups at differing risk for breast cancer (Bartow et al.,
1987). The three groups were all women from the New
Mexico and eastern Arizona area on whom autopsies were
performed by the New Mexico Medical Investigator's Office.
The deaths were usually sudden, unexpected and often
traumatic rather than a consequence of disease. Annual age
adjusted breast cancer incidence rates for women in this
geographic area are: Anglos (non-Hispanic whites), 81.4/
100,000; Hispanics, 54.1/100,000; and American Indians,
28.5/10,000 (Surveillance, Epidemiology, and End Results
(SEER), 1984).
In the original series, prevalence of marked fibrocystic
changes paralleled the breast cancer risk pattern (Bartow et
al., 1987). It was of interest to see if, within each ethnic/racial
group, the parity factors would show an effect on the
prevalence ofmorphologic fibrocystic changes independent of
ethnic/racial factors.
Materials and methods
A series of 519 women over the age of 14 was accumulated
from unselected consecutive autopsies of the New Mexico
Office of the Medical Investigator between December 1978
and December 1983. The women included Anglos, Hispanics,
and American Indians from New Mexico and eastern Arizona.
Twenty-nine women who were pregnant or immediately
post-partum at the time of death were excluded from con-
sideration for this study out of concern that an accurate
evaluation of fibrocystic change would not be possible in
these cases. Of the remaining 490 women, 336 had medical
history information available regarding nulliparous vs ever-
parous status (105 and 231, respectively). The distribution by
age, ethnic/racial group, and parity status of the 336 women
composing this study is shown in Table I.
The medical history of the women was obtained primarily
from family members of the deceased, either through
telephone interview or mail-in questionnaire. In 14 cases,
medical charts were the sole source of information. The
validity of surrogate information was ascertained by
preliminary field testing: Possible questions to be included
were asked of spouses, parents and/or children of a small set
of women, as well as test subjects themselves. There was
good correspondence between surrogate and primary sources
for the questions (regarding age at first birth and parity)
selected for inclusion in the final questionnaire.
Ethnic/racial identity was established at the time of
autopsy from information available to the medical investi-
gators. The assignments were corroborated by information
from interviews and questionnaires obtained from relatives
and close friends of the deceased. In cases of multiple
heritage, assignment was made according to the system used
by the New Mexico Registry. By this system, if a woman was
at least one-half American Indian, she was assigned to that
group. If she was one-half or more Hispanic and not at least
one-half American Indian, she was assigned to the Hispanic
group. Use of this ethnic/racial identification system allowed
for comparison of fibrocystic prevalence with known inci-
dence of breast cancer in these populations.
Autopsy in all cases was complete and included total
bilateral subcutaneous mastectomy. The breasts were fixed in
10% buffered formalin. Both breasts were sectioned at 1.0 cm
intervals and examined by a pathologist. Samples of tissue
for histologic examination were taken from the nipple area
and all four quadrants of both breasts by two methods. One
selection process was guided by the pathologist's impression
of areas that were representative of the overall breast tissue.
The other was by a defined protocol for random selection of
an area within a randomly selected slice. If the area selected
by the random process contained only fatty tissue, the sec-
tion closest to it containing parenchymal tissue was selected.
Both processes of tissue selection and later histologic evalua-
tion were carried out without the knowledge of clinical char-
acteristics of the case.
Histologic evaluation was of specific morphologic subsets
of 'fibrocystic change'. These subsets were evaluated individ-
ually rather than in a constellation because of increasing
evidence that breast cancer risk is associated with some, but
not all, of the subsets. Cystic change, apocrine metaplasia,
intraductal epithelial hyperplasia, sclerosing adenosis, and
lobular microcalcification were included in the histologic
evaluation. A scoring scheme was designed to give weighted
summary scores combining extent and degree of these
changes (Table II). Cystic change, apocrine metaplasia and
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Table I Number ofcases at given age at first full-term pregnancy and total
parity by ethnicity/race and age
Parity status Age at first birth Total parity
Ethnic/Race Age Never/Ever K20/21-24/ >25 1-2/ > 3
Anglo < 34 38/20 9/ 3/ 3 14/4
35-54 5/47 16/14/ 6 12/24
55 13/46 7/15/16 25/18
Hispanic 34 25/20 8/ 4/ 0 14/ 3
35-54 2/23 8/ 6/ 2 2/13
k55 1/20 8/ 1/ 1 4/12
Indian <34 16/24 8/ 3/ 4 8/ 8
35-54 4/18 5/ 4/ 1 4/ 5
>55 1/13 4/ 1/1 0/ 7
Table II Scoring methods
Individual slide
Raw score total for case:
final classification
Cystic change
Degree: 1 = mild
2 = moderate
3 = severe (> 3 mm)
Extent: 1 = few involved ducts
2 = moderate number of involved ducts
3 = majority of involved ducts
Apocrine metaplasia
1 = focal; 2 = multifocal; 3 = extensive
Intraductal epithelial hyperplasia
Degree: I = mild, up to four cell layers
2 = moderate, more than four cell layers,
occasional transluminal growth
3 = severe, transluminal growth frequent;
filling and distention of ducts
Extent: 1 = few involved ducts
2 = moderate number of involved ducts
3 = majority of involved ducts
intraductal epithelial hyperplasia were all scored for extent of
change (per cent of terminal ductules involved) within each
histologic section. In addition, cystic change and duct
epithelial hyperplasia were scored within each section for
degree of change, and scores for degree and extent were
added to determine the score for each individual histologic
section. Comparison of the mean score based only on the
random sections with the mean score based on pathologist
selection of the representative breast tissue did not show any
systematic differences between the two selection methods.
Thus, the total case score for any histologic parameter was
the sum of the individual scores from all 18 sections. Exam-
ples of 'atypical hyperplasia' by Page's criteria (Page et al.,
1985) were also recorded.
After determining the raw scores, these scores were divided
into two categories corresponding to minor and marked
degree of the change. The raw score ranges encompassed by
these categories varied with each histologic parameter. The
category of 'marked change' was based on sufficient change
being present to warrant being specified by the pathologist in
a diagnostic biopsy. Only 'marked change' was used for
analysis by parity parameters.
Information regarding parous or nulliparous status was
available on all 336 women. Age at first full-term pregnancy
could not be ascertained, and, for this study, age at first birth
was taken as a surrogate. For the 231 ever-parous women,
age at first birth was available on 158 (68%) women, and
total parity on 177 (77%). Initially, odds ratios for the
various parity parameters were calculated separately for each
ethnic/racial and age (<34, 35-54, > 55 years) category
(Mehta et al., 1986; Epidemiological Graphics, Estimation &
Testing Package, 1987). The basis for this age categorization
0-10: minor change
11 -96: marked change
0- 3: minor change
4-26: marked change
1- 7: minor change
8-41: marked change
was the observed changes in the levels of prevalence of
fibrocystic disease in these age groups (Bartow et al., 1987).
Fibrocystic changes were infrequent in the <34 years of age
group, peaked in the 35-54 years of age group, and
decreased in the > 55 years group. This age-related pattern
was seen in all three ethnic/racial groups.
Among the subsets of morphologic fibrocystic disease, cys-
tic change was the most common, followed by apocrine
metaplasia and intraductal epithelial hyperplasia. Only these
changes were included in the analysis by parity parameters.
Sclerosing adenosis and lobular microcalcification were too
uncommon for analysis. Three cases of atypical ductal and
two of atypical lobular hyperplasia were identified. All were
in women over 40 years of age. Comparison of the 336
women included in this study with the 154 who did not have
parity status information did not show any significant
differences in the prevalence of the various subsets of
fibrocystic disease considered in this study.
Summary odds ratios (ORs), adjusted for age and eth-
nicity, for the various histologic parameters by parity status
(Table III) were calculated using the exact stratified analysis
of 2 x k tables method in the EGRET statistical package
(Epidemiological Graphics, Estimation, and Testing
Package). Tests combining the ever/never-parous results with
the reduced data on parity and age at first birth used the
Mantel-Haenszel method. Tables with any zero marginals
were omitted from the summary results below.
Exact stratified analyses of 2 x k tables were also used for
calculating the odds ratios for the various histologic
parameters by ethnicity (Table IV) adjusted for age and
parity status.
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Table III Odds ratios (OR) and 95% confidence intervals (95% CI) for various fibrocystic change parameters
for ever-parous vs nulliparous women and for age at first birth and total parity in ever-parous women
Fibrocystic change parameters
Intraductal
Cystic Apocrine epithelial
change metaplasia hyperplasia
ORa ORa ORa
Parity variables No Yes (95% CI) No Yes (95% CI) No Yes (95% CI)
Neverb 75 30 1.00 93 12 1.0 95 10 1.0
Ever 148 83 0.80 199 32 0.71 199 32 0.72
(0.41-1.56) (0.28-1.85) (0.27-1.98)
Age at first birth
<20b 50 23 1.00 63 10 1.0 61 12 1.0
21-24 33 18 0.96 45 6 0.64 45 6 0.59
(0.34-2.71) (0.16-2.38) (0.15-2.03)
25 18 16 1.83 30 4 0.57 29 5 0.60
(0.55-6.26) (0.10-2.68) (0.12-2.49)
Total parity
1-2b 52 31 1.0 75 8 1.0 73 10 1.0
> 3 56 38 0.71 75 19 2.18 80 14 0.84
(0.29-1.66) (0.76-6.76) (0.27-2.58)
'All ORs adjusted for age and ethnicity. bReference category.
Table IV Odds ratios and (95% confidence intervals) for the fibrocystic change parameters in the three ethnic/racial groups adjusted for age
and parity parameters
Fibrocystic change parameters
Intraductal
Cystic Apocrine epithelial
change metaplasia hyperplasia
Adjustment American American American
variables Anglob Hispanic Indian Anglob Hispanic Indian Anglob Hispanic Indian
Agea 1.0 .38 .23 1.0 .89 .07 1.0 1.05 .17
(.19-.71) (.10-.49) (.39-1.91) (.00-.44) (.46-2.31) (.02-.73)
Age and 1.0 .38 .25 1.0 .90 .07 1.0 1.11 .19
Never/Ever (.19-.71) (.11-.53) (.40-1.95) (.00--47) (.48-2.48) (.02-.83)
Agea 1.0 .32 .11 1.0 .86 .00 1.0 1.28 .22
(.11-.88) (.02-.43) (.22-2.85) (.00-.97) (.39-4.56) (.00-1.63)
Age and 1.0 .37 .11 1.0 1.0 .00 1.0 1.36 .22
AFFTPC (.12-1.06) (.02-.44) (.23-3.93) (.00-.88) (.38-4.56) (.00-1.71)
Agea 1.0 .32 .13 1.0 .99 .00 1.0 1.28 .00
(.12-.77) (.03-.46) (.34-2.72) (.00-.84) (.42-3.63) (.00-1.04)
Age and 1.0 .32 .12 1.0 .80 .00 1.0 1.35 .00
Total parity (.13-.79) (.02-.42) (.26-2.26) (.00-.78) (.43-4.05) (.00-1.41)
aBased on cases with complete information for the corresponding parity parameter. bReference category. CAFFTP - age at first full term
pregnancy.
the formula for sample size calculations when comparing two
binomial distributions (Casagrande et al., 1978). Program
POWER in the EPILOG PLUS statistical package was used
for actual calculations (EPILOG PLUS, 1989).
Results
Marked cystic ductal dilatation was less common in parous
than in nulliparous women (OR = 0.81, Table III). Risk of
cystic change decreased with increasing parity and was lowest
in women who had a first birth before age 25. Increasing
parity was associated with a lower risk even after adjusting
for age at first birth (OR = 0.66), and the effect ofearlier age
at first birth also remained after adjusting for total parity
(ORs of 1.00, 0.83, 1.81 for <20, 21-24, 25 +, respectively).
None of these results was, however, statistically significant,
even when the ever/never-parous category result was com-
bined, statistically, with the results for age at first birth and
total parity: Mantel-Haenszel test for age at first birth plus
ever/never parous - Chi-square = 2.20 on 1 degree offreedom,
P = 0.14; Mantel-Haenszel test for total parity plus ever/
never parous - Chi-square = 0.95 on 1 degree of freedom,
P = 0.33.
Marked apocrine metaplasia was less common in parous
than in nulliparous women (OR = 0.71, Table III), but risk
increased with increasing parity and earlier age at first birth
so that it was not reasonable to combine the ever/never-
parous result with the total parity or age at first birth result.
The frequency of apocrine metaplasia was low and none of
the results was statistically significant.
Marked intraductal epithelial hyperplasia was less common
in parous than in nulliparous women (OR = 0.72, Table III),
and risk decreased with increasing parity although not with
earlier age at first birth. The frequency of intraductal
epithelial hyperplasia was also low and none of these results
was statistically significant, including the result combining,
statistically, the ever/never-parous result with the result for
total parity (Mantel-Haenszel test - Chi-square = 0.36 on 1
degree of freedom, P = 0.55).
Although none of the results reached statistical signifi-
cance, the prevalence of marked changes for all three histo-
logic parameters considered was consistently lower in the
ever-parous than in the nulliparous women. Sample size cal-
culations for a cohort design, showed that for cystic change,
if the prevalence of marked cystic change in nulliparous is
assumed to be .30, to detect OR = .75, at significance level
= .05 with power = .80, approximately 590 nulliparous and
1180 ever-parous women would be required i.e., five times
the current sample size. For apocrine metaplasia and intra-
ductal epithelial hyperplasia, if the prevalence of marked
changes in the nulliparous is assumed to be .15, to detect
OR = .75, at a= .05 with power = .80, approximately 1010
nulliparous and 2020 ever-parous women would be required
i.e., ten times the current sample size.
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differences in the prevalence of fibrocystic change were ob-
served in the three ethnic/racial groups in this series. To
assess whether some of these differences could be explained
by differences in distribution of the parity factors in the three
ethnic/racial groups, the histologic parameters were adjusted
for parity status (Table IV).
Marked cystic change paralled the breast cancer pattern
for the three ethnic/racial groups. When adjusted for age and
never/ever-parous status, all three groups differ from each
other, with cystic change being less common in Hispanics
than Anglos (OR =.38) and least common in American
Indians (OR= .25).
The pattern for marked apocrine metaplasia and intra-
ductal epithelial hyperplasia was different. The prevalence of
these histologic parameters did not differ between Anglos
and Hispanics but was significantly lower for American
Indians. This pattern persisted after adjustment for age and
never/ever-parous status (Table IV).
Discussion
Ever-parous vs nulliparous status, early age at first full-term
pregnancy and multiparity have been identified by
epidemiological studies as protective against the development
of breast carcinoma (MacMahon et al., 1970; Kelsey, 1979;
Bain et al., 1981; Lubin et al., 1982; Helmrich et al., 1983).
Although the effect of term pregnancy has been extensively
evaluated, the mechanism of this protection has not been
defined. One hypothesis is that full-term pregnancy changes
the breast epithelium in a way that renders it less susceptible
to carcinogenesis (Cairns, 1975).
Cairns postulated that the stem cells of breast epithelium
increase in number at puberty and then fluctuate with each
ovarian cycle. He hypothesised that each full-term pregnancy
induces more of these cells to fully differentiate with a result-
ant decrease in vulnerability to cancerous induction.
In humans, both carcinoma and most benign epithelial
proliferative lesions, recently identified as having the highest
association with carcinoma (Dupont & Page, 1985; Hutter et
al., 1986; Page et al., 1985) originate in the terminal ducts of
the lobular unit of the breast (Jensen et al., 1976). It is the
epithelial cells in these structures that show mitotic activity
and apoptosis resulting in architectural fluctuations during
the menstrual cycle, as well as in pregnancy (Longacre &
Bartow, 1986). If full-term pregnancy induces these cells to
fully differentiate, it would be reasonable to assume that
occurrence of pregnancy may protect against the develop-
ment of the putative precursor lesions of fibrocystic change
as well as against the development of cancer.
Berkowitz (Berkowitz et al., 1985) and Hsieh (Hsieh et al.,
1984), in their studies of risk factors for fibrocystic breast
disease, did not find an association between age at first birth
and the occurrence of fibrocystic change. However, Hsieh
found that women with high total parity were at decreased
risk for fibrocystic breast disease. Berkowitz observed a
similar effect ofhigh total parity, but only for premenopausal
women. No decrease in risk was observed for the ever-parous
as compared to nulliparous women in the Berkowitz study.
This comparison was not possible in the Hsieh series because
of the study design.
In this study, the odds ratios for significant fibrocystic
change based on ever-parous status were consistently lower
than 1. This is strongly suggestive of a protective effect of
parity against cystic change, apocrine metaplasia and in-
traductal epithelial hyperplasia. Increasing parity (3 + vs
1-2) was also associated with a slightly lower prevalence of
cystic change and intraductal epithelial hyperplasia, but even
after combining these results with those ever/never-parous
status, the results did not approach statistical significance.
This is the first attempt to examine the interaction of
parity parameters with fibrocystic change in a cohort of
unselected, consecutive autopsies. When designing this study,
no estimate was available. of the magnitude of the effects
which might be observed. Differences of the order indicated
by these results are, unfortunately, not measurable as statis-
tically significant with the number of cases in this series. Any
future study will need to include at least 1,000 nulliparous
and 2,000 parous women to detect such differences in preval-
ence of fibrocystic change induced by parity status as statis-
tically significant.
A potential limitation of this study was the lack of medical
information for all 519 cases, resulting in possible bias due to
nonrandom availability of information. However, com-
parisons of the mean scores for all the fibrocystic changes
between the subset of 336 women and the total series did not
show any systematic differences. Although inaccuracies re-
sulting from surrogate data were to some degree anticipated
in designing the questionnaire, undoubtedly some were intro-
duced from this source: this will have reduced the power of
the study through biasing the results towards 'no effect'.
The original study from which these cases were derived
was designed to see if the known ethnic/racial differences in
breast cancer incidence could be partially explained by
differences in distribution of fibrocystic breast changes in
these ethnic/racial groups. As can be seen in Table IV,
differences in prevalence of fibrocystic breast changes,
especially cystic change, generally parallels the breast cancer
incidence pattern for the three ethnic/racial groups. The
distribution of parity factors also differ in our samples from
these three groups, so that failure to adjust for parity status
could account for some of the differences in prevalence of the
histologic parameters. Adjustment for parity status did not,
however, alter the estimates of odds ratios for fibrocystic
change in the three ethnic/racial groups. Additionally,
differences in the distribution of relative body weight as
measured by Quetelet's index (weight in kilograms/height2 in
meters) also failed to account for the observed ethnic/racial
differences in odds ratios of fibrocystic change (unpublished
data). Thus, as with breast cancer, the ethnic/racial
differences of fibrocystic change prevalence remain un-
explained. This does not preclude the possibility that these
differences are determined by other less easily evaluated cul-
tural factors (e.g. diet) rather than genetic factors.
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